RWRobert S. Washburn

Robert S. Washburn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert S. Washburn has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

  • Open Access

    Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.

  • Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi, Samuel S. Pan, Jianhua Hu, Catherine A. Shu, Naiyer A. Rizvi, et al.

    Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.


  • Open Access

    Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade

    by Peter H. Wang, Robert Washburn, Rohan Maniar, Michael Mu, Olivia Ringham, Radomir Kratchmarov, Brian S. Henick, Steven L. Reiner

    Immune checkpoint blockade is limited by resistance to treatment, with many patients not achieving durable antitumor responses. Self-renewing (T cell factor 1+ [TCF1+]) CD8+ T cells have recently been implicated in efficacy of anti–programmed cell death protein 1 (anti–PD-1). Mice challenged with syngeneic tumors were treated with anti–PD-1 and/or a reversible inhibitor of PI3K δ, designed to promote T cell self-renewal. Growth of tumors in untreated mice was characterized by waning proportions of TCF1+ T cells, suggesting self-renewing T cells become limiting for successful immunotherapy. Higher proportions of TCF1+ T cells in tumor and blood correlated with better control of tumor growth. Combining anti–PD-1 and inhibitor of PI3K δ conferred superior protection compared with either monotherapy and was associated with higher frequency of TCF1+ T cells in tumor and blood compared with anti–PD-1 alone. These findings reveal predictive importance of self-renewing T cells in anti-tumor immunity and suggest that resistance-directed strategies to enhance T cell self-renewal could potentiate the efficacy of PD-1 blockade.


  • Open Access

    Abstract 1240: Peripherally measured T cell self-renewal capacity associates with response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC)

    by Rohan Maniar, Peter H. Wang, Robert S. Washburn, Naiyer A. Rizvi, Steven L. Reiner, Brian S. Henick

    Recent studies have suggested that ICB does not primarily restore function to terminally exhausted T cells, but instead drives proliferation and differentiation of progenitor T cells into fresh effector cells. T cell factor 1 (TCF1) marks and maintains T cell self-renewal while repressing differentiation and has been associated with increased antitumor activity. These findings suggest ICB may depend on the continued availability of self-renewing TCF1+ progenitor T cells as the source of fresh effector cells. We hypothesized that characterizing the immunophenotype of T cells in the peripheral blood, with a focus on markers of self-renewal, might be predictive of ICB response. Utilizing an institution-wide biospecimen repository, we evaluated peripheral blood samples using multi-parametric flow cytometry from patients with metastatic NSCLC treated with single-agent ICB who experienced durable clinical benefit (DCB; >1 year of treatment and/or clinical response >1 year) or primary resistance (RES; - T cell subset, which is characterized by lower proportions of TCF1+ cells but increase during active immune responses. We analyzed samples collected from a cohort of 22 patients, 11 of whom had DCB and 11 with RES. In the pre-treatment samples (n=22), we determined that the frequency of TCF1+CCR7- CD8+ T cells was significantly higher in patients with DCB compared to patients with RES (32.6% v. 19.0%; P = 0.0452). Importantly, the median progression free survival was 17.0 months in patients with TCF1+ frequency above the median compared to 3.0 months in patients with TCF1+ frequency below the median (HR 0.43; P = 0.0185). Among the on-treatment samples (n=19), there was an increased frequency of PD1+ expression within the CCR7- CD8+ T cell subset compared to the paired baseline samples. Examination of those therapy-expanded PD1+ T cells revealed differences in the composition of TCF1+ versus TCF1- fractions in relation to treatment outcome. The mean ratio of TCF1+ to TCF1- amongst PD1+CCR7- T cells on-treatment was found to be significantly higher in the DCB group (1.483 [DCB] v. 0.4791 [RES], P=+ CD8 T cells, but the presence of greater fractions of TCF1+ T cells in the PD1+ CD8 T cell population correlates with DCB. This finding suggests that persistence and mobilization of self-renewing progenitor T cells is associated with long-lived ICB-induced anti-tumor activity. Citation Format: Rohan Maniar, Peter H. Wang, Robert S. Washburn, Naiyer A. Rizvi, Steven L. Reiner, Brian S. Henick. Peripherally measured T cell self-renewal capacity associates with response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1240.